Stryker (SYK) Stock Forecast & Price Target

Compare

2,623 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SYK Analyst Ratings

Strong Buy

18 Buy

4 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Stryker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SYK Stock 12 Month Forecast

Average Price Target

$431.35

▲(24.74% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is $431.35 with a high forecast of $469.00 and a low forecast of $380.00. The average price target represents a 24.74% change from the last price of $345.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"350":"$350","380":"$380","410":"$410","440":"$440","470":"$470"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":469,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$469.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":431.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$431.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$380.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[350,380,410,440,470],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,387.02,393.32615384615383,399.6323076923077,405.9384615384615,412.2446153846154,418.5507692307692,424.85692307692307,431.1630769230769,437.46923076923076,443.7753846153846,450.08153846153846,456.3876923076923,462.69384615384615,{"y":469,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,387.02,390.43,393.84,397.25,400.65999999999997,404.07,407.48,410.89,414.3,417.71000000000004,421.12,424.53000000000003,427.94,{"y":431.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,387.02,386.47999999999996,385.94,385.4,384.86,384.32,383.78,383.24,382.7,382.15999999999997,381.62,381.08,380.54,{"y":380,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":383.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":379.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":376.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":356.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$469.00

Average Price Target$431.35

Lowest Price Target$380.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Nico Chen

DBS

$450

Buy

30.13%

Upside

Reiterated

03/18/26

DBS Remains a Buy on Stryker (SYK)

Danielle Antalffy

UBS

$400→$380

Hold

9.89%

Upside

Assigned

03/17/26

Stryker price target lowered to $380 from $400 at UBSStryker price target lowered to $380 from $400 at UBS

Travis Steed

Bank of America Securities

$450

Buy

30.13%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Stryker (NYSE: SYK) and Esperion (NASDAQ: ESPR)

Larry Biegelsen

Wells Fargo

$456

Buy

31.86%

Upside

Reiterated

03/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

$420

Buy

21.45%

Upside

Reiterated

03/11/26

Citi opens 'upside 90-day catalyst watch' on StrykerCiti opens 'upside 90-day catalyst watch' on Stryker

Rick Wise

Stifel Nicolaus

$440

Buy

27.24%

Upside

Reiterated

03/06/26

Stifel Nicolaus Keeps Their Buy Rating on Stryker (SYK)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$465

Buy

34.47%

Upside

Reiterated

03/05/26

Jefferies Reaffirms Their Buy Rating on Stryker (SYK)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

03/05/26

Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Stryker (SYK)

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

03/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunome (NASDAQ: IMNM), Hinge Health, Inc. Class A (NYSE: HNGE) and Stryker (NYSE: SYK)

Shagun Singh Chadha

RBC Capital

$435

Buy

25.79%

Upside

Reiterated

03/05/26

RBC Capital Remains a Buy on Stryker (SYK)

Ryan Zimmerman

BTIG

$412

Buy

19.14%

Upside

Reiterated

03/05/26

BTIG Keeps Their Buy Rating on Stryker (SYK)

Patrick Wood

Morgan Stanley

$445

Buy

28.68%

Upside

Reiterated

02/02/26

Stryker (SYK) Receives a Buy from Morgan Stanley

Jeff Johnson

Robert W. Baird

$450→$437

Buy

26.37%

Upside

Reiterated

01/30/26

Stryker price target lowered to $437 from $450 at BairdStryker price target lowered to $437 from $450 at Baird

Mathew Blackman

TD Cowen

$387

Hold

11.91%

Upside

Reiterated

01/30/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD), Radiopharm Theranostics Limited Sponsored ADR (NASDAQ: RADX) and Stryker (NYSE: SYK)

Matt Miksic

Barclays

$462→$469

Buy

35.62%

Upside

Reiterated

01/30/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Nico Chen

DBS

$450

Buy

30.13%

Upside

Reiterated

03/18/26

DBS Remains a Buy on Stryker (SYK)

Danielle Antalffy

UBS

$400→$380

Hold

9.89%

Upside

Assigned

03/17/26

Stryker price target lowered to $380 from $400 at UBSStryker price target lowered to $380 from $400 at UBS

Travis Steed

Bank of America Securities

$450

Buy

30.13%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Stryker (NYSE: SYK) and Esperion (NASDAQ: ESPR)

Larry Biegelsen

Wells Fargo

$456

Buy

31.86%

Upside

Reiterated

03/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

$420

Buy

21.45%

Upside

Reiterated

03/11/26

Citi opens 'upside 90-day catalyst watch' on StrykerCiti opens 'upside 90-day catalyst watch' on Stryker

Rick Wise

Stifel Nicolaus

$440

Buy

27.24%

Upside

Reiterated

03/06/26

Stifel Nicolaus Keeps Their Buy Rating on Stryker (SYK)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$465

Buy

34.47%

Upside

Reiterated

03/05/26

Jefferies Reaffirms Their Buy Rating on Stryker (SYK)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

03/05/26

Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Stryker (SYK)

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

03/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunome (NASDAQ: IMNM), Hinge Health, Inc. Class A (NYSE: HNGE) and Stryker (NYSE: SYK)

Shagun Singh Chadha

RBC Capital

$435

Buy

25.79%

Upside

Reiterated

03/05/26

RBC Capital Remains a Buy on Stryker (SYK)

Ryan Zimmerman

BTIG

$412

Buy

19.14%

Upside

Reiterated

03/05/26

BTIG Keeps Their Buy Rating on Stryker (SYK)

Patrick Wood

Morgan Stanley

$445

Buy

28.68%

Upside

Reiterated

02/02/26

Stryker (SYK) Receives a Buy from Morgan Stanley

Jeff Johnson

Robert W. Baird

$450→$437

Buy

26.37%

Upside

Reiterated

01/30/26

Stryker price target lowered to $437 from $450 at BairdStryker price target lowered to $437 from $450 at Baird

Mathew Blackman

TD Cowen

$387

Hold

11.91%

Upside

Reiterated

01/30/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD), Radiopharm Theranostics Limited Sponsored ADR (NASDAQ: RADX) and Stryker (NYSE: SYK)

Matt Miksic

Barclays

$462→$469

Buy

35.62%

Upside

Reiterated

01/30/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stryker

3 Months

xxx

Success Rate

15/22 ratings generated profit

Average Return

+4.87%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +4.87% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

18/25 ratings generated profit

Average Return

+10.87%

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +10.87% per trade.

2 Years

xxx

Success Rate

25/29 ratings generated profit

Average Return

+19.72%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.21% of your transactions generating a profit, with an average return of +19.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYK Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SYK has received 37 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SYK average Analyst price target in the past 3 months is 431.35.

Each month's total comprises the sum of three months' worth of ratings.

SYK Financial Forecast

SYK Earnings Forecast

Next quarter’s earnings estimate for SYK is $3.00 with a range of $2.92 to $3.07. The previous quarter’s EPS was $4.47. SYK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Sales Forecast

Next quarter’s sales forecast for SYK is $6.36B with a range of $6.21B to $6.49B. The previous quarter’s sales results were $7.17B. SYK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Stock Forecast FAQ

What is SYK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stryker Corporation’s 12-month average price target is 431.35.

What is SYK’s upside potential, based on the analysts’ average price target?

Stryker Corporation has 24.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SYK a Buy, Sell or Hold?

Stryker Corporation has a consensus rating of Strong Buy which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.

What is Stryker Corporation’s price target?

The average price target for Stryker Corporation is 431.35. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $469.00 ,the lowest forecast is $380.00. The average price target represents 24.74% Increase from the current price of $345.81.

What do analysts say about Stryker Corporation?

Stryker Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of SYK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Stryker (SYK) Stock Forecast & Price Target

SYK Analyst Ratings

SYK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stryker

SYK Analyst Recommendation Trends

SYK Financial Forecast

SYK Earnings Forecast

SYK Sales Forecast

SYK Stock Forecast FAQ

Detailed List of Analyst Forecasts